Chemotherapy for lung cancer: still alive!

被引:1
作者
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Allergy & Resp Med Thorac Oncol, Okayama, Japan
关键词
RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; OPEN-LABEL; COMPARING GEFITINIB; MULTICENTER; PACLITAXEL; ERLOTINIB; HYDRATION; AFATINIB;
D O I
10.1093/jjco/hyv074
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:609 / 610
页数:2
相关论文
共 12 条
  • [1] Short Hydration in Chemotherapy Containing Cisplatin (≥ 75 mg/m2) for Patients with Lung Cancer: A Prospective Study
    Horinouchi, Hidehito
    Kubota, Kaoru
    Itani, Hidetoshi
    Taniyama, Tomoko Katsui
    Nakamichi, Shinji
    Wakui, Hiroshi
    Kanda, Shintaro
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Tamura, Tomohide
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1105 - 1109
  • [2] Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002
    Hotta, Katsuyuki
    Takigawa, Nagio
    Hisamoto-Sato, Akiko
    Ichihara, Eiki
    Kudo, Kenichiro
    Uchida, Koji
    Yanase-Nakamura, Kayo
    Tanaka, Hisaaki
    Kato, Yuka
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1115 - 1123
  • [3] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Harada, M.
    Yoshizawa, H.
    Kinoshita, I.
    Fujita, Y.
    Okinaga, S.
    Hirano, H.
    Yoshimori, K.
    Harada, T.
    Saijo, Y.
    Hagiwara, K.
    Morita, S.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 54 - 59
  • [4] Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
    Kris, Mark G.
    Johnson, Bruce E.
    Berry, Lynne D.
    Kwiatkowski, David J.
    Iafrate, A. John
    Wistuba, Ignacio I.
    Varella-Garcia, Marileila
    Franklin, Wilbur A.
    Aronson, Samuel L.
    Su, Pei-Fang
    Shyr, Yu
    Camidge, D. Ross
    Sequist, Lecia V.
    Glisson, Bonnie S.
    Khuri, Fadlo R.
    Garon, Edward B.
    Pao, William
    Rudin, Charles
    Schiller, Joan
    Haura, Eric B.
    Socinski, Mark
    Shirai, Keisuke
    Chen, Heidi
    Giaccone, Giuseppe
    Ladanyi, Marc
    Kugler, Kelly
    Minna, John D.
    Bunn, Paul A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (19): : 1998 - 2006
  • [5] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) : 2380 - 2388
  • [6] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi, Tetsuya
    Morita, Satoshi
    Yatabe, Yasushi
    Negoro, Shunichi
    Okamoto, Isamu
    Tsurutani, Junji
    Seto, Takashi
    Satouchi, Miyako
    Tada, Hirohito
    Hirashima, Tomonori
    Asami, Kazuhiro
    Katakami, Nobuyuki
    Takada, Minoru
    Yoshioka, Hiroshige
    Shibata, Kazuhiko
    Kudoh, Shinzoh
    Shimizu, Eiji
    Saito, Hiroshi
    Toyooka, Shinichi
    Nakagawa, Kazuhiko
    Fukuoka, Masahiro
    [J]. LANCET ONCOLOGY, 2010, 11 (02) : 121 - 128
  • [7] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
    Miyauchi, Eisaku
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 670 - 676
  • [8] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, Rafael
    Carcereny, Enric
    Gervais, Radj
    Vergnenegre, Alain
    Massuti, Bartomeu
    Felip, Enriqueta
    Palmero, Ramon
    Garcia-Gomez, Ramon
    Pallares, Cinta
    Miguel Sanchez, Jose
    Porta, Rut
    Cobo, Manuel
    Garrido, Pilar
    Longo, Flavia
    Moran, Teresa
    Insa, Amelia
    De Marinis, Filippo
    Corre, Romain
    Bover, Isabel
    Illiano, Alfonso
    Dansin, Eric
    de Castro, Javier
    Milella, Michele
    Reguart, Noemi
    Altavilla, Giuseppe
    Jimenez, Ulpiano
    Provencio, Mariano
    Angel Moreno, Miguel
    Terrasa, Josefa
    Munoz-Langa, Jose
    Valdivia, Javier
    Isla, Dolores
    Domine, Manuel
    Molinier, Olivier
    Mazieres, Julien
    Baize, Nathalie
    Garcia-Campelo, Rosario
    Robinet, Gilles
    Rodriguez-Abreu, Delvys
    Lopez-Vivanco, Guillermo
    Gebbia, Vittorio
    Ferrera-Delgado, Lioba
    Bombaron, Pierre
    Bernabe, Reyes
    Bearz, Alessandra
    Artal, Angel
    Cortesi, Enrico
    Rolfo, Christian
    Sanchez-Ronco, Maria
    Drozdowskyj, Ana
    [J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246
  • [9] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Mok, Tony
    Geater, Sarayut Lucien
    Orlov, Sergey
    Tsai, Chun-Ming
    Boyer, Michael
    Su, Wu-Chou
    Bennouna, Jaafar
    Kato, Terufumi
    Gorbunova, Vera
    Lee, Ki Hyeong
    Shah, Riyaz
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Schuler, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3327 - +
  • [10] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    Wu, Yi-Long
    Zhou, Caicun
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Lee, Kye Young
    Xu, Chong-Rui
    Massey, Dan
    Kim, Miyoung
    Shi, Yang
    Geater, Sarayut L.
    [J]. LANCET ONCOLOGY, 2014, 15 (02) : 213 - 222